D-Aminolevulinic acid

D-Aminolevulinic acid

Clinical data
ATC code	L01XD04 (WHO)
Identifiers
IUPAC name 5-amino-4-oxo-pentanoic acid
CAS Number	106-60-5
PubChem CID	137
DrugBank	APRD00793
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C5H9NO3
Molar mass	131.13 g/mol

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

D-Aminolevulinic acid (dALA or δ-ALA or 5-aminolevulinic acid) is the first compound in the porphyrin synthesis pathway, the pathway that leads to hemoglobin in mammals.

• The presence of δ-aminolevulinic acid in the urine is a key guideline for patients suspected of having porhyria use
• Normal values: <7.5 mg/24h urine in a 20ml urine sample.

In non-photosynthetic eukaryotes such as animals, insects, fungi, and protozoa as well as the α-proteobacteria group of bacteria it is produced by the enzyme ALA synthase, from glycine and succinyl CoA. This reaction is known as the Shemin pathway.

In plants, algae, bacteria (except for the α-proteobacteria group) and archaea it is produced from glutamic acid via glutamyl-tRNA and glutamate-1-semialdehyde. The enzymes involved in this pathway are glutamyl-tRNA synthetase, glutamyl-tRNA reductase and glutamate-1-semialdehyde aminotransferase. This pathway is known as the C5 or Beale pathway.

Test Indications

• Acute intermittent porphyria
• Chronic hepatic porphyria
• Drug damage to the liver
• Hereditary coproporphyria
• Porphyria variegata

Clinical significance

It elicits synthesis and accumulation of fluorescent porphyrins (protoporphyrin IX) in epithelia and neoplastic tissues, among them malignant gliomas. It is used to visualise tumorous tissue in neurosurgical procedures. Studies have shown that the intraoperative use of this guiding method may reduce the tumour residual volume and prolong progression-free survival in patients suffering from this disease.

dALA is also a photosensitizer for photodynamic therapy.

See also

• Porphyrin

Template:WikiDoc Sources Template:Jb1